Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 2, 2015, Pages 294-304

  Reischig, Tomas ^a   Kacer, Martin ^a   Jindra, Pavel ^a   Hes, Ondrej ^a   Lysak, Daniel ^a   Bouda, Mirko ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS INFECTION; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; ACICLOVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; VALINE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; OPEN STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VIREMIA; ACUTE DISEASE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CZECH REPUBLIC; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GRAFT REJECTION; IMMUNOLOGY; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ACUTE DISEASE; ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; BIOMARKERS; BIOPSY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CZECH REPUBLIC; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VALINE; VIRAL LOAD;

EID: 84923809198     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07020714     Document Type: Article

References (39)

1. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group: Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96: 333–360, 2013.
2. Reischig T, Jindra P, Svecova´ M, Kormunda S, Opatrny´ K Jr., Treska V: The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 36: 146–151, 2006.
3. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V: Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 87: 436–444, 2009.
4. Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA: Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21: 1579–1586, 2010.
5. Humar A, Gillingham K, Payne WD, Sutherland DE, Matas AJ: Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 70: 310–313, 2000.
6. Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, Nordal KP, Jenssen T: Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 47: 1550–1556, 2004.
7. Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degre´ M, Fauchald P, Rollag H: Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66: 329–337, 2004.
8. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR: Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46: 840–846, 2008.
9. Luan FL, Kommareddi M, Ojo AO: Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 11: 1936– 1942, 2011.
10. Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O: Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 23: 1588–1597, 2012.
11. Reischig T: Advances in cytomegalovirus-preventive strategies in solid organ transplantation: Defending pre-emptive therapy. Expert Rev Anti Infect Ther 10: 51–61, 2012.
12. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10: 1228–1237, 2010.
13. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F: Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 8: 975–983, 2008.
14. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P: Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study. Transplantation 90: 1427–1431, 2010.
15. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6: 2134–2143, 2006.
16. Reischig T, Jindra P, Hes O, Svecova´ M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8: 69–77, 2008.
17. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340: 1462–1470, 1999.
18. Kielberger L, Bouda M, Jindra P, Reischig T: Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res 35: 407–416, 2012.
19. Reischig T, Jindra P, Mares J, Cechura M, Svecova´ M, Hes O, Opatrny´ K Jr., Treska V: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79: 317–324, 2005.
20. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring: American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6: 262–274, 2006.
21. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A: Banff’09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 10: 464–471, 2010.
22. Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN: A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect 11: 736–743, 2005.
23. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4: 611–620, 2004.
24. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A: Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 56: 817–824, 2013.
25. Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC: Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 90: 412–418, 2010.
26. Kalil AC, Freifeld AG, Lyden ER, Stoner JA: Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoSONE 4: e5512, 2009.
27. Reischig T: Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 8: 903–910, 2010.
28. Freeman RB Jr.: The ‘indirect’ effects of cytomegalovirus infection. Am J Transplant 9: 2453–2458, 2009.
29. Dzabic M, Rahbar A, Yaiw KC, Naghibi M, Religa P, Fellstro¨mB, Larsson E, So¨derberg-Naucle´ r C: Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 53: 969–976, 2011.
30. Reischig T, Nemcova´ J, Vanecek T, Jindra P, Hes O, Bouda M, Treska V: Intragraft cytomegalovirus infection: A randomized trial of valacyclovir prophylaxis versus preemptive therapy in renal transplant recipients. Antivir Ther 15: 23–30, 2010.
31. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG:Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143: 870–880, 2005.
32. Heagy W, Crumpacker C, Lopez PA, Finberg RW: Inhibition of immune functions by antiviral drugs. J Clin Invest 87: 1916–1924, 1991.
33. Battiwalla M, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, Segal BH, Wallace PK, Nakamura R, Padmanabhan S, Hahn T, McCarthy PL Jr.:Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 13: 765–770, 2007.
34. Reischig T, Prucha M, Sedlackova L, Lysak D, Jindra P, Bouda M, Matejovic M: Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther 16: 1227–1235, 2011.
35. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice: BK polyomavirus in solid organ transplantation. Am J Transplant 13[Suppl 4]: 179–188, 2013.
36. Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, Mayr M: Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 10: 2615–2623, 2010.
37. Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, Hirsch HH: Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. AmJ Transplant 7: 1131–1139, 2007.
38. Bestard O, Lucia M, Crespo E, Van Liempt B, Palacio D, Melilli E, Torras J, Llaudo´ I, Cerezo G, Taco O, Gil-Vernet S, Grinyo´ JM, Cruzado JM: Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 13: 1793–1805, 2013.
39. Kayler L, Zendejas I, Schain D, Magliocca J: Ureteral stent placement and BK viremia in kidney transplant recipients. Transpl Infect Dis 15: 202–207, 2013.